Abstract
EE359 Cost-Effectiveness of Pembrolizumab + Chemotherapy Versus Cetuximab-Containing Regimens ‘Extreme’ and ‘TPEx’, for R/M SCCHN Patients with a CPS between 1 and 19, in Italy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have